Skip to main content

Table 1 Baseline characteristics of patients

From: Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy

 

Patients, no. (%)

All patients

n = 3565

Asthma

n = 2013

Possible asthma

n = 157

Non-asthmatic COPD

n = 1395

FEV1 ↓ > 15% (%)

222 (6.2)

152 (7.5)

22 (14.0)

48 (3.4)

Male sex (n, %)

1569 (44.0)

708 (40.3)

100 (63.7)

761 (54.5)

Age year (mean, SD)

54 (17)

47 (17)

44 (13)

66 (11)

ICS (n, %)

1957 (54.9)

1661 (82.5)

102 (65)

194 (13.9)

LABA (n, %)

2426 (68)

1381 (68.6)

51 (32.5)

994 (71.3)

OCS (n, %)

174 (4.9)

135 (6.7)

8 (5.1)

31 (2.2)

NB (n, %)

328 (16.6)

106 (5.3)

15 (9.6)

207 (14.8)

EB (n, %)

592 (13.8)

534 (26.5)

20 (12.7)

37 (2.7)

FEV1 % (mean, SD)

62.5 (45.5)

68.7 (33.6)

78.4 (22.5)

59.8 (40.8)

FEV1/VC % (mean, SD)

64.4 (37.0)

68.7 (43.7)

72.2 (24.6)

54.6 (34.5)

  1. ICS inhaled corticosteroid, NB neutrophilic bronchitis, EB eosinophilic bronchitis, OCS oral corticosteroid, regular or intermittent, LABA long-acting β-agonist
  2. Eosinophilic bronchitis (EB) was defined as percentage of sputum eosinophils ≥ 3%. Neutrophilic bronchitis (NB) was defined as a total cell count ≥ 15 million cells/g of sputum and proportion of neutrophils ≥ 64%